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ABSTRACT

HUMAN ORGANIC ANION TRANSPORTERS 1 AND 3: STRUCTURAL ELEMENTS
IMPACTING TRANSPORTER-SUBSTRATE BINDING INTERACTIONS
By Julie Nguyen
Bachelor of Science, University of Virginia, Charlottesville, Virginia, USA
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2021
Director: Douglas H. Sweet, Ph.D.
Professor,
Department of Pharmaceutics, School of Pharmacy
Organic anion transporters (OATs) are known to interact with a wide variety of
negatively charged drugs and can impact their clinical safety and efficacy profiles. The
U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have
recognized and highlighted the importance of evaluating the potential interactions with
transporters, specifically hOAT1 and hOAT3, during the development of new drug
entities. Little is known about OAT-drug interactions as they are difficult to discern on a
molecular level in the absence of any solved crystal structures for OATs. Therefore, in a
previous study, in silico homology models of hOAT1 and hOAT3 were generated based
on the solved crystal structure for Piriformospora indica phosphate transporter (PiPT).
The models were docked with their respective prototypical substrates, amino acid
contacts involved in substrate recognition predicted, and single point mutations
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generated. Following mutagenesis, singly mutated hOAT1 and hOAT3 transporters were
subject to accumulation and saturation studies to determine their role in substrate binding
and subsequent translocation. The findings from this previous study indicated singly
mutated constructs did not result in altered binding affinity (Km). However, the question
remained whether these predicted amino acid contacts would significantly alter affinity
when present in various double and triple combinations.
In

this

study,

multiple

combination

hOAT1

(Arg15Lys/Ile19Leu,

Ile19Leu/Tyr230Phe, Arg15Lys/Tyr230Phe, and Arg19Lys/Ile19Leu/Tyr230Phe) and
hOAT3 mutants (Phe426Tyr/Phe430Ser and Phe426Tyr/Phe430Tyr) were generated
and functional accumulation screens were conducted to determine the impact on overall
transport activity. Mutants that retained transport activity were then further assessed by
kinetic assays to determine any changes in Km. Functional accumulation screens showed
none of the hOAT1 multiple mutants retained PAH transport activity. In contrast, the
generated hOAT3 double mutants retained ES transport activity. Subsequent kinetic
analysis revealed the hOAT3 double mutants exhibited no statistically significant changes
in estimated Km values as compared to hOAT3 wild-type.
This study provides further insight as to the importance of these predicted critical
amino acid residues in substrate binding interactions. Further characterizing these
molecular interactions will allow for improved manipulation of drug substrate
pharmacokinetics as well as prediction of drug-drug interactions, both of which can be
utilized in drug design and development.
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CHAPTER 1
1.A INTRODUCTION
Transporters have gained attention in the field of pharmacology as they are
expressed throughout our bodies and play important roles in the absorption, distribution,
and excretion of endogenous and exogenous substances, including drugs. There are two
major superfamilies of membrane-bound transporters: ATP binding cassette (ABC) and
solute carrier (SLC) transport proteins. ABC transporters directly bind and hydrolyze ATP
to drive the translocation of substrates across the cell membrane. Whereas, SLCs are
indirectly coupled to cellular energy and use ion gradients (e.g., symporters and
antiporters) as well as electrochemical potential (e.g., facilitated diffusion) to drive
transcellular transport of substrates (Figure 1.1) [11]. Among the 65 SLC families, the
SLC22 family comprises anion/cation/zwitterion transporters [3,22,24]. Organic anion
transporters (OATs) are a subtype of the SLC22 transport proteins that are responsible
for the membrane translocation of negatively charged organic substrates such as toxins,
nutrients, and drugs [14,16,22].
Twenty-nine transporters have been identified as potential members within the
SLC22 family; many of which have been characterized in terms of transport mechanism,
substrate and inhibition profiles, and tissue distribution [24]. Two of these members,
OAT1 (SLC22A6) and OAT3 (SLC22A8), are further investigated in this project. OATs
are proposed to have 12 alpha helical transmembrane domains (TMDs) with a large
extracellular loop between TMDs 1 and 2, a large intracellular loop between TMDs 6 and
7, and cytosolic amino and carboxyl termini [9,17]. In humans, OAT1 and OAT3 share
expression in the eye, brain, and kidneys while OAT1 and OAT3 are found in the placenta
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and liver, respectively. Furthermore, they are highly expressed in the kidneys and
targeted to the basolateral membrane of renal proximal tubule cells [15,20,21].
Additionally, they have high amino acid sequence similarity (50%) and are often
expressed in the same cell types. Furthermore, while their specificities overlap, they often
have different affinities for the same compound. This redundancy in substrate recognition
may serve as an evolutionary survival mechanism that likely provides additional transport
capacity in the following situations: 1) environmental exposure to toxic compounds, 2)
drug-drug interactions, 3) genetic dysfunction

(e.g., gene variants), and 4)

pathophysiological states (e.g., renal insufficiency) [23]. In renal proximal tubule cells,
human OAT1 (hOAT1) and OAT3 (hOAT3) are specifically responsible for mediating the
absorption of organic anion substrates from the blood across the cell membrane via a
dicarboxylate/organic anion antiport mechanism (Figure 1.1) [11,22]. Prototypical
substrates for hOAT1 (para-aminohippurate, or PAH) and hOAT3 (estrone sulfate, or ES)
are exchanged for α-ketoglutarate (α-KG), the only known physiological counterion. Efflux
of substrates occurs through facilitated diffusion carriers and/or efflux transporters.
In addition to the prototypical substrates, hOAT1 and hOAT3 bind to a wide variety
of structurally diverse negatively charge compounds under physiological conditions (i.e.,
pH 7.4) including NSAIDs (e.g., indomethacin), antivirals (e.g., acyclovir), β-lactam
antibiotics (e.g., penicillin), diuretics (e.g., furosemide), and chemotherapeutic agents
(e.g., cisplatin) [4,5,6]. OATs impact the pharmacokinetics and pharmacodynamics of
several dozens of drugs, potentially altering their clinical safety and efficacy profiles. Both
the U.S. Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) have issued guidances that recognize the importance of in vitro studies of
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investigational new drugs to be evaluated as potential substrates or inhibitors for
transporters known to be involved in drug interactions [1,7,13]. These guidances
specifically identify hOAT1 and hOAT3 as transporters that need to be evaluated for
potential interactions with the new chemical entity and to determine if further in vivo
studies are required regarding potential drug-drug interactions [1,7,13]. Thereby,
highlighting the importance of studying the structure-activity relationship of hOAT1 and
hOAT3 in drug substrate binding interactions.
As several substances are known to interact with hOAT1 and hOAT3 for renal
elimination, gaining a better understanding of the biochemical binding mechanisms of
OATs is vital to predict their pharmacokinetics as well as therapeutic safety and efficacy.
Doing so potentially allows transporter-substrate interactions to be manipulated to
maximize efficacy and minimize renal toxicity [12]. For example, renal elimination can be
slowed by optimizing transporter-drug interactions to decrease binding affinity. This may
be used to improve the therapeutic effects of a poorly bioavailable drug as well as to lower
its dosage or dosing frequency. Furthermore, generating compounds that have greater
specificity for a transporter and are co-formulated as excipients (e.g., probenecid) may
decrease drug-drug interactions and/or allow for preferential competitive binding at target
transporters [12]. Ultimately, identifying and characterizing critical amino acids involved
in substrate recognition for hOAT1 and hOAT3 may offer great insight into drug design to
control pharmacokinetics as well as to better predict drug-drug interactions.
The lack of structural information (i.e., no solved crystal structure) for OATs has
made it challenging to understand these molecular interactions [17]. In order to study
substrate binding via hOAT1 and hOAT3, in silico homology models of each transporter
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were previously generated based on the solved crystal structure of Piriformospora indica
phosphate transporter (PiPT) [8]. Substrates were docked and from these models amino
acids potentially critical to binding interactions were determined (Figure 1.2 and Figure
1.3). Subsequently, single mutants were generated (Table 1.1 and Table 1.2) and
screened for transport activity [8]. Initial accumulation studies revealed hOAT1
substitutions Arg15Lys, Ile19Leu, and Tyr230Phe and hOAT3 substitutions Phe426Tyr,
Phe430Ser, and Phe430Tyr retained sufficient transport activity to pursue saturation
analyses. For hOAT1, saturation analyses showed none of the single mutants had
significantly altered affinity (Km) compared to wild-type. For hOAT3, one single mutant
(Phe430Ser) showed significantly altered Km compared to wild-type suggesting weaker
binding affinity. These findings suggest that a single mutation is insufficient to significantly
impact affinity, however double or triple combinations of these mutants could potentially
have a greater impact on substrate binding and transport kinetics. Thus, in this project,
we explored the hypothesis that multiple mutant combinations are needed to significantly
alter hOAT1 and hOAT3 substrate binding affinity through the following specific aims:
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1.B SPECIFIC AIMS
Specific Aim 1
To test the hypothesis that double and triple combinations of point mutants at
predicted critical substrate binding contacts will result in altered substrate binding
affinity for hOAT1, we:
a. Generated double/triple mutants using site-directed mutagenesis.
b. Established stably transfected cell lines expressing hOAT1 mutants.
c. Identified active and inactive mutants via substrate accumulation assays.
d. Determined the binding affinity of active mutants and their prototypical
substrate PAH.
Specific Aim 2
To test the hypothesis that double and triple combinations of point mutants at
predicted critical substrate binding contacts will result in altered substrate binding
affinity for hOAT3, we:
a. Generated double mutants using site-directed mutagenesis.
b. Established stably transfected cell lines expressing hOAT3 mutants.
c. Identified active and inactive mutants via substrate accumulation assays.
d. Determined the binding affinity of active mutants and their prototypical
substrate ES.
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Figure 1.1. Model depicting driving forces for OAT1 and OAT3 transport.
Mechanisms/driving forces used for cellular entry and exit for organic anion transport
using renal proximal tubule cell as an example.
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Figure 1.2. Different rotational views of the hOAT1-PAH binding complex.
The five amino acids predicted to be important for PAH binding and transport are
indicated. Image files generated using PyMOL 1.8.
[Figure taken from reference [8]]
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Table 1.1. Summary of putative PAH-hOAT1 complex forming amino acids, the
predicted nature of each interaction and generated conservative and nonconservative hOAT1 mutations.

[Table taken from reference [8]]
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Figure 1.3. Different rotational views of the hOAT3-ES binding complex.
The five amino acids predicted to be important for ES binding and transport are indicated.
Image files generated using PyMOL 1.8.
[Figure taken from reference [8]]
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Table 1.2. Summary of putative ES-hOAT3 complex forming amino acids, the
predicted nature of each interaction and generated conservative and nonconservative hOAT3 mutations.

[Table taken from reference [8]]
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CHAPTER 2

IDENTIFYING STRUCTURAL ELEMENTS OF HUMAN ORGANIC ANION
TRANSPORTERS 1 AND 3 MEDIATING SUBSTRATE-TRANSPORTER BINDING
INTERACTIONS

2.A INTRODUCTION
Previously studied hOAT1 and hOAT3 transport active single mutants were
combined to generate double and/or triple mutants. Multiple combination mutants were
stably expressed in CHO or HEK cells in order to determine retention of transport function.
Functional screening indicated none of the hOAT1 mutants, but both of the hOAT3 double
mutants (Phe426Tyr/Phe430Ser and Phe436Tyr/Phe430Tyr) exhibited significant
changes in substrate accumulation as compared to parental cells. Saturation analysis of
transport active hOAT3 double mutants indicated no change in affinity as compared to
hOAT3 wild-type.
2.B MATERIALS AND METHODS
2.B.1 Chemicals and Reagents
Mutagenesis and sequencing primers were purchased from Integrated DNA
Technologies (Coralville, IA). The QuikChange Lightning Site-Directed Mutagenesis Kit
and DH5-α cells were purchased from Agilent Technologies (Santa Clara, CA). hOAT3
mutants were purchased from GenScript. Lipofectamine transfection reagents,
Dulbecco’s Modified Eagle/Ham’s F-12 Medium (DMEM/F12), and Dulbecco’s Modified
Eagle Medium with high glucose (DMEM/HIGH GLUCOSE) were purchased from Thermo
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Fisher Scientific (Waltham, MA). QIAprep spin miniprep kits were purchased from
QIAGEN (Germantown, MD). Geneticin (G418) and Penicillin-Streptomycin were
purchased from Gibco-Invitrogen (Grand Island, NY). [H3] PAH was purchased from
PerkinElmer Life and Analytical Science (Waltham, MA). Unlabeled PAH and probenecid
were purchased from Sigma-Aldrich (St. Louis, MO). Ecoscint H cocktail was purchased
from National Diagnostics (Atlanta, GA). Bradford protein assay dye was purchased from
Bio-Rad Laboratories. GoTaq green master mix was purchased from Promega (Madison,
WI).
2.B.2 hOAT1 Mutant Generation
Using previously constructed hOAT1 single point mutants as template, hOAT1
double and triple combination mutants were constructed using the QuikChange Lightning
Site-Directed Mutagenesis Kit according to the manufacturer’s recommendations [2].
Briefly, the single mutant template (for double combination mutants) or the double mutant
template (for triple combination mutant) was denatured, primers annealed to the template
to introduce the additional desired mutation(s), and the mutant DNA strand elongated.
Samples were incubated with Dpn1 restriction enzyme to degrade hOAT1 wild-type
template strands. Oligonucleotide primers containing the desired mutations are reported
in Table 2.1.
2.B.3 hOAT3 Mutant Generation
Multiple attempts at generating hOAT3 double combination mutants with the
previously described method for hOAT1 were unsuccessful. Following reanalysis of the
desired mutation positions, it was discovered there was wild-type sequence in the
mutagenesis primers that overlapped mutant sequence in the template. Therefore,
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primers that would introduce both desired mutations at once were generated to construct
hOAT3 double mutants. After these generation attempts failed, hOAT3 double mutants
were synthesized by GenScript in order to move forward with subsequent
experimentation. Sequences used to generate the desired hOAT3 mutants are reported
in Table 2.2.
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Table 2.1. Oligonucleotide primers used for hOAT1 site-directed mutagenesis.
Template

Mutagenesis Substitution
Position

R15K

19

I19L

230

Isoleucine →
Leucine

Tyrosine →
Phenylalanine

Primers (5’ - 3’)

Final Mutant

Forward

CCGCTTCCAGCAGTTGCAGGTCACCCTGG

R15K/I19L

Reverse

CCAGGGTGACCTGCAACTGCTGGAAGCGG

Forward

I19L/Y230F

GGGCACCTTGATTGGCTATGTCTTTAGCCTGGGCCAG
Reverse
CTGGCCCAGGCTAAAGACATAGCCAATCAAGGTGCCC

R15K

230

Tyrosine →
Phenylalanine

Forward

R15K/Y230F

GGGCACCTTGATTGGCTATGTCTTTAGCCTGGGCCAG
Reverse
CTGGCCCAGGCTAAAGACATAGCCAATCAAGGTGCCC

R15K/I19L

230

Tyrosine →
Phenylalanine

Forward

R15K/I19L/Y230F

GGGCACCTTGATTGGCTATGTCTTTAGCCTGGGCCAG
Reverse
CTGGCCCAGGCTAAAGACATAGCCAATCAAGGTGCCC
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Table 2.2. hOAT3 site-directed mutagenesis.
Template Mutagenesis Substitution
Position
Wild-type

426 & 430

Sequence Substitution

426: Phenylalanine → Forward
Tyrosine
CCTATCCAGCTCCTACAGCTGCCTCTCCCTCTACACAAGT

Final Mutant
F426Y/F430S

430: Phenylalanine → Reverse
Serine
ACTTGTGTAGAGGGAGAGGCAGCTGTAGGAGCTGGATAGG

Wild-type

426 & 430

426: Phenylalanine → Forward
Tyrosine
CCTATCCAGCTCCTACAGCTGCCTCTACCTCTACACAAGT
430: Phenylalanine → Reverse
Tyrosine
ACTTGTGTAGAGGTAGAGGCAGCTGTAGGAGCTGGATAGG

15

F426Y/F430Y

2.B.4. Bacterial Transformation
hOAT1 and hOAT3 mutant plasmids were transformed into XL10-Gold
Ultracompetent and DH5-α cells, respectively, according to the manufacturer’s protocol
[2]. Transformed bacterial cells were spread on LB agar plates containing ampicillin (0.1
mg/mL) and incubated at 37°C for 16 hrs. Individual colonies were picked and incubated
for 16 hrs in 5 mL LB broth containing 0.1 mg/mL ampicillin at 37°C while being shaken
at 225 RPM.
2.B.5 Mutant Confirmation
Plasmid DNA from the overnight culture was isolated and purified using QIAGEN’s
Mini-Prep Kit following the manufacturer’s protocol [18]. Briefly, bacterial cultures were
pelleted, resuspended, lysed, neutralized, and centrifuged at 13,000 RPM for 10 min. The
supernatant was applied to the spin columns where plasmid DNA binds to, and
contaminating material is washed from, the column. Following elution of the purified
plasmid DNA from the column, DNA concentration and purity were determined using UVVis spectroscopy. hOAT1 and hOAT3 mutants were confirmed by DNA sequencing
(Genewiz, South Plainfield, NJ) with the primers in Table 2.3 and Table 2.4, respectively.
The presence of the desired mutations was confirmed by comparing sequence files and
chromatograms for the mutants against hOAT1 and hOAT3 wild-type.
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Table 2.3. Oligonucleotide primers used for hOAT1 DNA sequencing.
Primer

Primer Sequence (5’ - 3’)

hOAT1 Forward 1

CCCATCTACCATCGTGACTG

hOAT1 Forward 2

AGTCTGCAGAAGGAGCTGAC

hOAT1 Reverse 1

CATTGAGCAGGATGCAGATG

hOAT1 Reverse 2

AAGTTGGGTGCGAAGGCTGC

T7

TAATACGACTCACTATAGGG

BGHR

TAGAAGGCACAGTCGAGG
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Table 2.4. Oligonucleotide primers used for hOAT3 DNA sequencing.
Primer

Primer Sequence (5’ - 3’)

hOAT3 Forward 1

TGGTCTTCCGCTTCCTGTG

hOAT3 Forward 2

CTTAAGCTACCTGGGCC

hOAT3 Reverse 1

CTAGGATCAGTCTCTGGAGG

hOAT3 Reverse 2

CCTCCGAGGACTTTCCAGAC

T7

TAATACGACTCACTATAGGG

BGHR

TAGAAGGCACAGTCGAGG
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2.B.6 Transfection and Cell Culture
Stable Chinese hamster ovary (CHO) and human embryonic kidney (HEK 293) cell
lines expressing confirmed mutant transporters were generated for hOAT1 and hOAT3,
respectively, using cationic lipid-based transfection according to the Lipofectamine 2000
Reagent protocol [10]. Briefly, 1 μg plasmid DNA and 4 μL Lipofectamine 2000 were
mixed, diluted with OptiMEM, and applied to cells at 70-80% confluency in 12-well tissue
culture plates. Prior to seeding for hOAT3 mutant transfections, tissue culture plates were
coated with 0.1 mg/mL poly-D-lysine. Fresh DMEM/F12 and DMEM/HIGH GLUCOSE
containing 10% FBS was added to each well for hOAT1 and hOAT3 mutant transfections,
respectively, prior to adding the plasmid DNA/Lipofectamine 2000/OptiMEM mixture.
After incubating for 24 to 48 hrs at 37°C with 5% CO2, the transfection medium was
replaced with fresh medium containing G418 (1mg/mL) for 2 to 3 weeks of antibiotic
selection. Cells viable in the presence of G418 were moved to culture flasks and
maintained under antibiotic selective pressure (0.25 mg/mL G418). All CHO and HEK 293
cells lines were maintained in DMEM/F12 and DMEM/HIGH GLUCOSE, respectively,
containing 10% FBS, 1% Penicillin-Streptomycin, and 0.25 mg/mL G418 (for transporter
expressing cell lines) at 37°C with 5% CO2. Cells were subcultured once they reached
80-90% confluency.
2.A.7 Accumulation Assay Screen
Generated mutants were tested for transport activity via cell accumulation assays.
Briefly, cells were seeded in 24-well tissue culture plates at 250,000 cells/well in the
absence of antibiotics 48 hrs before the experiment. For all assays involving HEK 293
cells, tissue culture plates were coated with 0.1 mg/mL poly-D-lysine. Culture medium
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was removed and cells were equilibrated at room temperature for 10 min with 500 µL
transport buffer (TB). Cells were incubated in 400 µL TB containing 5 µM PAH (or ES)
spiked with 0.25 µCi/mL [H3] PAH (or [H3] ES) in the presence or absence of the inhibitor
probenecid (500 µM). After a 10 min incubation, treatment was removed and cells were
immediately washed three times with ice-cold TB. Cells were lysed with 200µL 1N NaOH,
neutralized with 250 µL 1N HCl, and 200 µL 10 mM HEPES. Radioactivity in cell lysates
was quantified by liquid scintillation counting using 400 µL of sample and 5 mL Ecoscint
H cocktail. Substrate accumulation was determined from background corrected counts
and normalized by the protein content as determined via a Bradford protein assay using
10 µL of sample and 200 µL protein assay dye. Accumulation values were corrected for
background accumulation (diffusion) in parental CHO and HEK 293 cells via linear
regression (Y = mX+b) as appropriate. Initial activity screen values were reported as
average ± SD from triplicate samples.
2.B.8 Kinetic Assay
The Michaelis-Menten constant (Km) was determined for PAH and ES on active
hOAT1 and hOAT3 mutants, respectively, via saturation analysis. Mutant expressing cells
were seeded in 24-well tissue culture plates at 250,000 cells/well in the absence of
antibiotics 48 hrs before the experiment. For all assays involving HEK 293 cells, tissue
culture plates were coated with 0.1 mg/mL poly-D-lysine. Culture medium was removed
and cells were equilibrated at room temperature for 10 min with 500µL TB. Cells were
incubated in 400 µL TB containing increasing concentration of PAH (1-200 µM PAH or
ES) spiked with 0.25 µCi/mL [H3] PAH (or [H3] ES). After a 1 min incubation, treatment
was removed and cells were immediately washed three times with ice-cold TB. Cells were
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lysed with 200 µL 1N NaOH, neutralized with 250 µL 1N HCl, and 200 µL 10 mM HEPES.
Radioactivity in cell lysates was quantified by liquid scintillation counting using 400 µL of
sample and 5 mL Ecoscint H cocktail. Substrate accumulation was determined from
background corrected counts and normalized by the protein content as determined via a
Bradford protein assay using 10 µL of sample and 200 µL protein assay dye.
Accumulation values were corrected for background accumulation (diffusion) in parental
CHO and HEK 293 cells via linear regression (Y = mX+b) as appropriate. Transporter
mediated

uptake

was

plotted

and

analyzed

using

nonlinear

regression

(Y = Vmax*X/(Km + X)) in GraphPad Prism (GraphPad Software Inc., San Diego, CA) to
generate Km estimates. Km estimates from individual experiments were reported as
average ± SD from triplicate samples. Final Km estimates from at least two independent
experiments were reported as average ± SE.
2.B.9 Statistics
Data are plotted as average ± SD for initial screen and saturation assays. Oneway ANOVA with post-hoc Dunnett’s multiple comparisons were used to determine
differences compared to a single control for initial screens. Differences were considered
statistically significant if p < 0.05. Final Km estimates are reported as average ± SE.
GraphPad Prism version 9.1.0 was used for statistical analysis.
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2.C RESULTS
2.C.1 hOAT Mutant DNA Confirmation
All hOAT1 and hOAT3 mutant constructs were confirmed by DNA sequencing.
Figure 2.1 shows chromatograms for the hOAT1 Arg15Lys/Ile19Leu double mutants. In
Figure 2.1A, the hOAT1 Arg15Lys single mutant template sequence shows an AAG
codon for lysine at position 15 and an ATC codon for isoleucine at position 19. In Figure
2.1B, the mutated TTG codon for leucine is observed. Figure 2.2 shows chromatograms
for the hOAT1 Ile19Leu/Tyr230Phe double mutant. In Figure 2.2A, the hOAT1 Ile19Leu
single mutant template sequence shows a TTG codon for leucine at position 19 and a
TAC codon for tyrosine at position 230. In Figure 2.2B, the mutated TTT codon for
phenylalanine is observed. Figure 2.3 shows chromatograms for the hOAT1
Arg15Lys/Tyr230Phe double mutant. In Figure 2.3A, the hOAT1 Arg15Lys single mutant
template sequence shows an AAG codon for lysine at position 15 and a TAC codon for
tyrosine at position 230. In Figure 2.3B, the mutated TTT codon for phenylalanine is
observed.

Figure

2.4

Arg15Lys/Ile19Leu/Tyr230Phe

shows
triple

chromatograms
mutant.

In

Figure

for
2.4A,

the
the

hOAT1
hOAT1

Arg15Lys/Ile19Leu double mutant template sequence shows an AAG codon for lysine at
position 15, a TTG for leucine at position 19, and a TAC for tyrosine at position 230. In
Figure 2.4B, the mutated TTT codon for phenylalanine is observed.
Figure 2.5 shows chromatograms for the hOAT3 double mutants generated. In
Figure 2.5A, the hOAT3 wild-type template sequence shows a TTC codon for
phenylalanine at positions 426 and 430. In Figure 2.5B, the mutated TAC codon for
tyrosine and TCC codon for serine at positions 426 and 430, respectively, are observed.
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In Figure 2.5C, the mutated TAC codons for tyrosine are observed at positions 426 and
430.
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Position 15

Position 19

A

B

Figure 2.1. Chromatograms for DNA sequencing confirmation of hOAT1
Arg15Lys/Ile19Leu double mutant.
The chromatograms for hOAT1 Arg15Lys single mutant (A) and hOAT1
Arg15Lys/Ile19Leu double mutant (B) DNA sequence. Arg15Lys was used as a template
and position 19 was mutated. The highlighted regions show the mutated position as well
as the amino acid that is translated as a result.
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Position 19

Position 230

A

B

Figure 2.2. Chromatograms for DNA sequencing confirmation of hOAT1
Ile19Leu/Tyr230Phe double mutant.
The chromatograms for hOAT1 Ile19Leu single mutant (A) and hOAT1
Ile19Leu/Tyr230Phe double mutant (B) DNA sequence. Ile19Leu was used as a template
and position 230 was mutated. The highlighted regions show the mutated position as well
as the amino acid that is translated as a result.
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Position 15

Position 230

A

B

Figure 2.3. Chromatograms for DNA sequencing confirmation of hOAT1
Arg15Lys/Tyr230Phe double mutant.
The chromatograms for hOAT1 Arg15Lys single mutant (A) and hOAT1
Arg15Lys/Tyr230Phe double mutant (B) DNA sequence. Arg15Lys was used as a
template and position 230 was mutated. The highlighted regions show the mutated
position as well as the amino acid that is translated as a result.
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Position 15

Position 19

Position 230

A

B

Figure 2.4. Chromatograms for DNA sequencing confirmation of hOAT1 Arg15Lys/Ile19Leu/Tyr230Phe triple
mutant.
The chromatograms for hOAT1 Arg15Lys/Ile19Leu double mutant (A) and hOAT1 Arg15Lys/Ile19Leu/Tyr230Phe triple
mutant (B) DNA sequence. Arg15Lys/Ile19Leu was used as a template and position 230 was mutated. The highlighted
regions show the mutated position as well as the amino acid that is translated as a result.
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Position 426

Position 430

A

B

C

Figure 2.5. Chromatograms for DNA sequencing confirmation of hOAT3 double
mutants.
The chromatograms for hOAT3 wild-type (A), hOAT3 Phe426Tyr/Phe430Ser double
mutant (B), and hOAT3 Phe426Tyr/Phe430Tyr double mutant (C) DNA sequence.
hOAT3 wild-type was used as a template and positions 426 and 430 were mutated. The
highlighted regions show the mutated position as well as the amino acid that is translated
as a result.
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2.C.2 Accumulation Assay Screen
Accumulation assays were performed with stably-expressing cell lines to determine
overall transport activity of cells expressing wild-type and mutant hOAT1 (Figure 2.6 and
Figure 2.7) and hOAT3 (Figure 2.8). Initially, only one functional screen for hOAT1, which
will be referred to as “Round 1 functional screen”, was used to determine transport activity
and inactivity of the hOAT1 mutants (Figure 2.6). In Figure 2.6, hOAT1 wild-type cells
(113.0 ± 2.6 pmol/mg protein/10 min) showed significant PAH accumulation
approximately 31 fold higher than CHO parental cells (3.6 ± 2.7 pmol/mg protein/10 min).
PAH accumulation in the probenecid exposed hOAT1 wild-type cells (7.8 ± 2.7 pmol/mg
protein/10 min) is comparable to that of the CHO parental cells (3.6 ± 1.5 pmol/mg
protein/10 min), demonstrating nearly complete inhibition of transport activity. A one-way
ANOVA with Dunnett’s multiple comparison test between hOAT1 mutants and CHO
parent were performed to determine whether hOAT1 mutants were active or inactive.
hOAT1 mutants Arg15Lys/Ile19Leu (18.1 ± 6.6 pmol/mg protein/10 min) and
Ile19Leu/Tyr230Phe (15.2 ± 3.5 pmol/mg protein/10 min) appeared to retain PAH
transport activity and were statistically different from CHO parent (p < 0.05), suggesting
these two are transport active mutants. PAH accumulation in hOAT1 mutants
Arg15Lys/Tyr230Phe

(9.9

±

2.2

pmol/mg

protein/10

min)

and

Arg15Lys/Ile19Leu/Tyr230Phe (7.1 ± 3.5 pmol/mg protein/10 min) were not statistically
different from CHO parent, indicating they are transport inactive mutants.
Due to lack of transport activity observed (as described below in Kinetic Assays), a
second accumulation assay (Figure 2.7), which is referred to as “Round 2 functional
screen” was done to reassess active and inactive hOAT1 mutants. In Figure 2.7, hOAT1
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wild-type cells (21.8 ± 1.1 pmol/mg protein/10 min) showed significant PAH accumulation
approximately seven-fold higher than CHO parental cells (3.2 ± 0.3 pmol/mg protein/10
min). PAH accumulation in the probenecid exposed hOAT1 wild-type cells (4.0 ± 0.6
pmol/mg protein/10 min) is comparable to that of the CHO parental cells (3.1 ± 0.9
pmol/mg protein/10 min), demonstrating nearly complete inhibition of transport activity.
hOAT1

mutants

Arg15Lys/Ile19Leu

(4.3

±

0.4

pmol/mg

protein/10

min),

Ile19Leu/Tyr230Phe (4.3 ± 0.2 pmol/mg protein/10 min), Arg15Lys/Tyr230Phe (4.7 ± 0.2
pmol/mg protein/10 min), and Arg15Lys/Ile19Leu/Tyr230Phe (5.2 ± 1.1 pmol/mg
protein/10 min) did not retain significant PAH transport activity as compared to CHO
parent. A one-way ANOVA with Dunnett’s multiple comparison test between hOAT1
mutants and CHO parent was performed to determine whether hOAT1 mutants were
active or inactive. Only one hOAT1 mutant (Arg15Lys/Ile19Leu/Tyr230Phe) was
statistically

different

from

CHO

parent

(p

<

0.05).

Although,

Arg15Lys/Ile19Leu/Tyr230Phe was statistically different from CHO parent, it was
ultimately

considered

inactive

because

PAH

accumulation

in

Arg15Lys/Ile19Leu/Tyr230Phe was comparable in the presence (3.6 ± 0.5 pmol/mg
protein/10 min) and absence (5.3 ± 1.1 pmol/mg protein/10 min) of probenecid, indicating
there was no inhibitable transport activity (as described below in Discussion). All hOAT1
mutants were considered transport inactive according to the Round 2 functional screen.
In Figure 2.8, hOAT3 wild-type cells (399.6 ± 2.7 pmol/mg protein/10 min) showed
significant ES accumulation approximately nine-fold higher than HEK 293 parental cells
(42.6 ± 25.2 pmol/mg protein/10 min). ES accumulation in the probenecid exposed
hOAT3 wild-type cells (14.1 ± 4.1 pmol/mg protein/10 min) is comparable to that of the
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HEK 293 parental cells (19.0 ± 7.8 pmol/mg protein/10 min), demonstrating nearly
complete inhibition of transport activity. hOAT3 mutants Phe426Tyr/Phe430Ser (234.4 ±
30.0 pmol/mg protein/10 min) and Phe426Tyr/Phe430Tyr (366.0 ± 20.2 pmol/mg
protein/10 min) retained statistically significant ES transport activity compared to HEK 293
parent (p < 0.0001) and were considered transport active mutants.
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hOAT1 Mutant Screen
hOAT1
CHO Parent

*

R15K/I19L
R15K/Y230F

****
**

I19L/Y230F
R15K/I19L/Y230F
0

10

20

30 80 100 120 140

PAH Uptake
(pmol/mg protein/10 min)

Figure 2.6. Round 1 functional screening of hOAT1 mutants.
Cells were incubated in 5 µM PAH spiked with 0.25 µCi/mL [H3] PAH in the absence
(gray) or presence (black) of 500 µM probenecid (inhibitor) for 10 min. Y-axis labels
indicate the stably-expressing hOAT1 cell line tested including hOAT1 wild-type and the
double and triple hOAT1 mutants. CHO parental cells were used as a measure of
background activity. Accumulation values were normalized for protein content. Values
reported as average ± SD of triplicate samples. Significance indicated by ****p < 0.0001,
*p < 0.05 and **p < 0.01 compared to CHO parent as determined by one-way ANOVA
followed by Dunnett’s t-test. Image was generated using GraphPad Prism.
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Figure 2.7. Round 2 functional screening of hOAT1 mutants.
Cells were incubated in 5µM PAH spiked with 0.25 µCi/mL [H3] PAH in the absence (gray)
or presence (black) of 500µM probenecid (inhibitor) for 10 min. Y-axis labels indicate the
stably-expressing hOAT1 cell line tested including hOAT1 wild-type and the double and
triple hOAT1 mutants. CHO parental cells were used as a measure of background activity.
Accumulation values were normalized for protein content. Values reported as average ±
SD of triplicate samples. Significance indicated by ****p < 0.0001 and *p < 0.05 compared
to CHO parent as determined by one-way ANOVA followed by Dunnett’s t-test. Image
was generated using GraphPad Prism.
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hOAT3 Mutant Screen
hOAT3

****

HEK Parent

****

F426Y/F430S

****

F426Y/F430Y
0

100

200
300
400
ES Uptake
(pmol/mg protein/10 min)

500

Figure 2.8. Representative functional screening of hOAT3 mutants.
Cells were incubated in 5 µM ES spiked with 0.25 µCi/mL [H3] ES in the absence (gray)
or presence (black) of 500 µM probenecid (inhibitor) for 10 min. Y-axis labels indicate the
stably-expressing hOAT3 cell line tested including hOAT3 wild-type and the double
hOAT3 mutants. HEK 293 parental cells were used as a measure of background activity.
Accumulation values were normalized for protein content. Values reported as average ±
SD of triplicate samples. Significance indicated by ****p < 0.0001 compared to HEK 293
parent as determined by one-way ANOVA followed by Dunnett’s t-test. The functional
screen was repeated a second time for N=2. Image was generated using GraphPad
Prism.
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2.C.3 Kinetic Assays
Based on the hOAT1 Round 1 functional screen (Figure 2.6), Arg15Lys/Ile19Leu
and Ile19Leu/Tyr230Phe appeared to retain transport activity. Therefore, saturation
analysis was conducted on these mutants to determine PAH affinity changes compared
to hOAT1 wild-type. However, no transport activity was observed for any of the active
hOAT1 mutants (data not shown). Subsequently, a time course experiment was
conducted to determine if the linear range of uptake was extended for each mutant (Figure
2.9). As shown, substrate uptake in hOAT1 wild-type and hOAT1 mutants is linear
through one min and 10 min, respectively. Therefore, a second kinetic assay (1-200 µM
PAH) was conducted with an increased accumulation time of 10 min for each mutant was
performed. No transport activity was observed for Ile19Leu/Tyr230Phe (data not shown)
while potential transport activity was observed for Arg15Lys/Ile19Leu (Figure 2.10). It was
unclear whether Arg15Lys/Ile19Leu was saturated with PAH at increasing concentrations
of 1-200 µM. An additional assay was conducted with a broader PAH concentration range
(10-2000 µM), however saturable Arg15Lys/Ile19Leu mediated uptake was not observed
(Figure 2.11).
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Figure 2.9. Representative time course of PAH uptake by hOAT1 wild-type and
hOAT1 active mutants.
Cells were incubated in 5 µM PAH spiked with 0.25µCi/mL [H3] PAH for 1–15 min.
Accumulation values were corrected for background and protein content. Values reported
as average ± SD of triplicate samples. The time course was repeated a second time for
N=2. Image generated using GraphPad Prism.
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Figure 2.10. Saturation analysis of CHO hOAT1 Arg15Lys/Ile19Leu
CHO hOAT1 Arg15Lys/Ile19Leu was incubated in increasing concentrations of PAH (1–
200 μM) spiked with 0.25µCi/mL [H3] PAH for 10 min. Values were corrected for
background and protein content. Image generated using GraphPad Prism.
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Figure 2.11. Saturation analysis of CHO hOAT1 Arg15Lys/Ile19Leu.
CHO hOAT1 Arg15Lys/Ile19Leu was incubated in increasing concentrations of PAH (10–
2000 μM) spiked with 0.25µCi/mL [H3] PAH for 10 min. Values were corrected for
background and protein content. Image generated using GraphPad Prism.
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Kinetic analysis was performed on transport active hOAT3 mutants to determine
changes in Km compared to hOAT3 wild-type. All mutant expressing cell lines showed
saturable transport activity (Figure 2.12) and final Km estimates are summarized in Table
2.5. As shown, neither hOAT3 mutant Phe426Tyr/Phe430Ser (14.4 ± 3.0 pmol/mg
protein/1 min) nor Phe426Tyr/Phe430Tyr (16.7 ± 0.3 pmol/mg protein/1 min) exhibited
statistically different Km estimates as compared to wild-type hOAT3 (12.5 ± 3.4 pmol/mg
protein/1 min).
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A: wild-type
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Figure 2.12. Representative saturation analysis for hOAT3 wild-type and active mutants.
(A) hOAT3 wild-type, (B) hOAT3 Phe426Tyr/Phe430Ser, and (C) hOAT3 Phe426Tyr/Phe430Tyr cell lines were incubated
in increasing concentrations of ES (1–200 μM) spiked with 0.25µCi/mL [H3] ES for 1 min. Values were corrected for
background and protein content. Km estimates were determined using Michaelis-Menten nonlinear regression in GraphPad
Prism and reported as average ± SD of triplicate samples. A representative curve of the cell lines is shown in each panel.
For hOAT3 wild-type and Phe426Tyr/Phe430Ser, saturation assays were repeated three times for N=3. For hOAT3
Phe426Tyr/Phe430Tyr, saturation assays were repeated twice for N=2.
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Table 2.5. Estimated Km for hOAT3 wild-type and hOAT3 active mutants.
Transporter

Km (µM)

N

hOAT3 wild-type

12.5 ± 3.4

3

hOAT3 F426Y/F430S

14.0 ± 1.8

3

hOAT3 F426Y/F430Y

16.7 ± 0.3

2

Values reported as average ± SE.
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2.D DISCUSSION
There has been increasing interest in OATs as they are known to interact with a
broad variety of structurally diverse substrates, which makes them key contributors to the
pharmacokinetics of many therapeutics as well as highly susceptible to drug-drug
interactions. Therefore, from a clinical standpoint, gaining a better understanding of the
biochemical interactions between hOATs and their substrates is essential to improve drug
efficacy, better manage and predict drug-drug interactions, and even potentially influence
drug design. Currently, there is no solved crystal structure for any of the OATs, and
because of this lack of structural information, it is difficult to study OAT-substrate binding
interactions. For this reason, in silico homology models of hOAT1 and hOAT3 were
previously generated using the solved crystal structure of PiPT as template [8]. PiPT is
currently the best available template as it belongs to the same transporter superfamily,
shares relatively high protein sequence similarity to hOAT1 (33%) and hOAT3 (31%), is
evolutionarily related to the OATs, as it is a eukaryotic protein, and is crystalized in its
occluded state [8]. In addition, the International Transporter Consortium (ITC) has
identified PiPT as the preferred template moving forward [19]. Previously, docking studies
were performed between the hOAT1 and hOAT3 homology models and their prototypical
substrates to determine amino acid residues that may potentially be involved in substrate
recognition [8]. Single mutants were generated at the predicted contact amino acids,
screened for transport activity, and kinetic analysis was pursued with transport active
mutants. Findings from this previous study indicated that a single mutation is insufficient
to elicit a statistically significant change in binding affinity of prototypical substrates [8].
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Therefore, in this project, we study the impact of double and triple mutant combinations
on binding affinity.
In order to test whether the previously generated hOAT1 and hOAT3 single mutants
would bring about a significant change in affinity when combined, double and triple
mutants were generated for hOAT1 and hOAT3 as appropriate (Table 2.1 and Table 2.2).
For hOAT1, the Round 1 functional screen (Figure 2.6) revealed what appeared to be two
active mutants (Arg15Lys/Ile19Leu, p < 0.05 and Ile19Leu/Tyr230Phe, p < 0.01). Not only
was their PAH accumulation statistically significantly different from CHO parent, it was
also at least two to three times above CHO parental background which is the standard
criteria for determining whether a system is sufficiently robust to pursue kinetic analysis.
However, a saturation assay at 1-200 µM PAH and one minute uptake showed no
saturable transport activity (data not shown). To explore the possibility that the hOAT1
mutants had an extended linear range of uptake and that an extended accumulation time
was required for sufficient signal to accumulate, a time course experiment was conducted.
It was determined that the linear range of uptake was extended through at least 10 min
for both hOAT1 active mutants (Figure 2.9). Upon conducting saturation experiments for
10 min, no transport activity was observed for Ile19Leu/Tyr230Phe, but no transport
activity (Km = 5.1 ± 12 µM) was detected for Arg15Lys/Ile19Leu (Figure 2.10). The hOAT1
Arg15Lys/Ile19Leu mutation may have resulted in a weaker binding affinity (increased
Km), so the PAH concentration range for the saturation assay was extended in order to
ensure accurate Km estimation. Therefore, another saturation assay from 10-2000 µM
PAH with 10 min uptake was conducted. However, robust, saturable transport activity for
hOAT1 Arg15Lys/Ile19Leu (Km = 1542.2 ± 1379.2 µM) was not observed under these
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conditions (Figure 2.11). Given the lack of uptake and extreme error associated with
attempted kinetic analysis, the mutant appeared transport inactive. Therefore, the single
functional screen (Figure 2.6) was repeated as statistically different transport activity seen
in the Round 1 functional screen may have been due to improper washing following
substrate exposure. In the Round 2 functional screen (Figure 2.7), where washing volume
and time were increased post-substrate incubation to minimize variation between
replicates, all hOAT1 mutants were found to be inactive, as PAH accumulation was not
significantly

different

from

CHO

parental

background.

While

Arg15Lys/Ile19Leu/Tyr230Phe was statistically significant compared to hOAT1 wild-type,
the PAH accumulation was not two to three times CHO parental background activity, a
required parameter in order to have a system that is considered robust enough to pursue
kinetic analyses. Additionally, a paired t-test comparing PAH in the presence and absence
of probenecid for Arg19Lys/Ile19Leu/Tyr230Phe indicated that there is no statistical
difference (p < 0.05) between the two, suggesting once again that the triple mutant is
transport inactive. The single mutations Arg15Lys, Ile19Leu, and Tyr230Phe were
considered transport active mutants in previous studies [8]. Double and triple
combinations of these hOAT1 mutants resulted in transport inactivity, potentially
indicating that these mutations have disrupted multiple contacts within the binding site
and that multiple substrate contacts are needed to stably bind and translocate PAH.
These findings suggest that the hydrogen bond (Arg15), hydrophobic interaction (Ile19),
and edge-face Pi system (Tyr230) all need to be present in order for the transporter to
recognize PAH [8]. Since all hOAT1 mutants were considered transport inactive as there
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was insufficient transport activity to pursue kinetic analysis, no further studies were
conducted.
PAH transport inactivity observed for the hOAT1 mutants may be due to the
following: 1) the mutation disrupted binding interaction(s) critical for substrate recognition
or 2) the mutation disrupted proper protein folding and/or targeting to the plasma
membrane. Previously, hOAT1 membrane localization via Western blotting, GFP-fusion
constructs, and c-Myc tagged constructs was attempted, however all with inconclusive
results [8]. When examined in hOAT1, hOAT2 and hOAT3 expressing cell lines, no
transporter specific signal was associated with the commercial hOAT1 or hOAT3
antibodies via Western blotting [8]. The GFP-fusion constructs exhibited extensive
cytoplasmic fluorescent signal, preventing conclusive evaluation at the cell surface (i.e.,
membrane targeting) [8]. Immunohistochemistry was conducted on c-Myc tagged
constructs with a commercial c-Myc antibody, but again no transporter specific signal was
observed for controls [8]. Membrane targeting of inactive mutant transporter constructs
remains an unresolved issue.
Initial

functional

screening

indicated

both

hOAT3

double

mutants,

Phe426Tyr/Phe430Ser and Phe426Tyr/Phe430Tyr (p < 0.0001), retained ES transport
activity that is statistically different from HEK 293 parental background (Figure 2.8). Based
on the functional screen, both hOAT3 mutants recognize and transport ES, but it is
unknown whether the double mutant combinations altered the affinity for ES. Therefore,
saturation assays were conducted on these mutants to estimate the kinetic parameter Km
(Figure 2.12). For the current study, the hOAT3 wild-type Km for ES is 12.5 ± 3.4 µM
(Table 2.5), which is in agreement with previous literature values [22]. In previous single
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mutant studies, the estimated Km values for Phe426Tyr (13.4 ± 2.9 µM) and Phe430Tyr
(13.6 ± 0.2 µM) were not significantly different from wild-type [8]. However, the estimated
Km value for the combined Phe426Tyr/Phe430Tyr mutant (16.7 ± 0.3 µM) found in this
study is similar to that of hOAT3 wild-type (Table 2.5). Similarly, the estimated Km value
for Phe426Tyr/Phe430Ser (14.4 ± 3.0 µM) is not significantly different from hOAT3 wildtype (Table 2.5). Previously, there was a significant increase in Km with the single mutant
Phe430Ser (26.8 ± 5.0 µM) [8]. Surprisingly, in combination with Phe426Tyr
(Phe426Tyr/Phe430Ser) exhibited affinity similar to that of wild-type hOAT3. These
findings suggest that Phe426 and Phe430 may somehow interact with each other in order
to bind ES. Perhaps, the hydroxyl groups on the tyrosine and serine at both of these
amino acid positions is necessary for the hydrophobic interactions that occur and having
just one amino acid mutated disrupts the molecular interactions that occur.
In summary, initial accumulation assays demonstrated that double and triple
combination mutations resulted in loss of transport activity in all hOAT1 mutants. There
was no loss in transporter function for hOAT3 double combination mutations at positions
426 and 430. Furthermore, hOAT3 double mutants did not significantly alter the binding
affinity, indicating a degree of tolerance as well as a potential interaction between the
amino acids at these positions. Future work will focus on proper protein trafficking to the
plasma membrane, which would strengthen the interpretation that these contact points
actually play a role in substrate binding interactions. While all hOAT1 multiple mutants
resulted in a complete loss of transport activity for PAH, these mutants could retain
transport function for other substrates as they may have different amino acid contacts.
Future work will evaluate the impact of these hOAT1 mutants on transport activity of other
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hOAT1 substrates. Based on this study, it may be possible that hOAT3 positions 426 and
430 work in conjunction for ES recognition. In the future, kinetic studies with other hOAT3
substrates can further characterize these amino acid contacts. Once better characterized,
hOAT1 and hOAT3 modeling studies could serve as tools to asses and optimize new
chemical entities in terms of drug design. Furthermore, modeling studies could be utilized
to predict drug-drug interactions, which aids in decisions for continued finance and pursuit
of an investigational new drug.

47

LIST OF REFERENCES
1.
2.
3.
4.
5.
6.
7.

8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

U.S. Food and Drug Administration. In Vitro Drug Interaction StudiesCytochrome P450 Enzyme-and Transporter-Mediated Drug Interactions Guidance
for Industry. 2020.
Agilent Technologies. QuikChange Lightning Site-Directed Mutagenesis Kit.
2011.
Bai X, Moraes TF, Reithmeier RAF. Structural Biology of Solute Carrier (SLC)
Membrane Transport Proteins. Mol Membr Biol 34: 1–32, 2017.
Burckhardt G. Drug Transport by Organic Anion Transporters (OATs). Pharmacol.
Ther. 136: 106–130, 2012.
Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The Antiviral
Nucleotide Analogs Cidofovir and Adefovir are Novel Substrates for Human and
Rat Renal Organic Anion Transporter 1. Mol Pharmacol 56: 570–580, 1999.
Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol 14:
1248–1257, 2019.
Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC,
Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. Decreased
Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic
Anions in OAT1 Knock-Out Mice. J Biol Chem 281: 5072–5083, 2006.
Jay C. 3-D Homology Modeling of Organic Anion Transporters (OATS): Defining
the Biochemical Basis for OAT-Substrate Interactions. 2019.
Koepsell H. The SLC22 Family With Transporters of Organic Cations, Anions and
Zwitterions. Mol Aspects Med 34: 413–435, 2013.
Invitrogen. Lipofectamine 2000 User Guide. 2013.
Lai RE, Jay CE, Sweet DH. Organic Solute Carrier 22 (SLC22) Family: Potential
for Interactions With Food, Herbal/Dietary Supplements, Endogenous Compounds,
and Drugs. J. Food Drug Anal. 26: S45–S60, 2018.
Lin L, Yee SW, Kim RB, Giacomini KM. SLC Transporters as Therapeutic
Targets: Emerging Opportunities. Nat. Rev. Drug Discov. 14: 543–560, 2015.
European Medicines Agency. Guideline on the Investigation of Drug Interactions.
2012.
Mor AL, Kaminski TW, Karbowska M, Pawlak D. New Insight Into Organic Anion
Transporters From the Perspective of Potentially Important Interactions and Drugs
Toxicity. J. Physiol. Pharmacol. 69: 307–324, 2018.
Motohashi H, Saito H, Masuda S, Fukatsu A. Gene Expression Levels and
Immunolocalization of Organic Ion Transporters in the Human Kidney. J Am Soc
Nephrol 13: 866–874, 2002.
Nigam SK, Bush KT, Martovetsky G, Ahn S-Y, Liu HC, Richard E, Bhatnagar
V, Wu W. The Organic Anion Transporter (OAT) Family: A Systems Biology
Perspective. Physiol Rev 95: 83–123, 2015.
Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB. A Three-Dimensional Model
of Human Organic Anion Transporter 1: Aromatic Amino Acids Required for
Substrate Transport. J Biol Chem 281: 38071–38079, 2006.
Qiagen. QIAprep Miniprep Handbook. 2020.
Schlessinger A, Yee SW, Sali A, Giacomini KM. SLC classification: An update.

48

20.
21.
22.
23.

24.

Clin. Pharmacol. Ther. 94: 19–23, 2013.
Sekine T, Endou H. Immunolocalization of Multispecific Organic Anion
Transporters, OAT1, OAT2, and OAT3, in Rat Kidney. J Am Soc Nephrol 13: 848–
857, 2002.
Tojo A, Sekine T, Nakajima N, Hosoyamada M, Kanai Y, Kimura K, Endou H.
Immunohistochemical Localization of Multispecific Renal Organic Anion
Transporter 1 in Rat Kidney. J Am Soc Nephrol 10: 464–471, 1999.
Wang L, Sweet DH. Renal Organic Anion Transporters (SLC22 Family):
Expression, Regulation, Roles in Toxicity, and Impact on Injury and Disease. AAPS
J. 15: 53–69, 2013.
Zhu C, Nigam KB, Date RC, Bush KT, Springer SA, Saier MH, Wu W, Nigam
SK. Evolutionary Analysis and Classification of OATs, OCTs, OCTNs, and Other
SLC22 Transporters: Structure-Function Implications and Analysis of Sequence
Motifs. PLOS One 10:1–20, 2015.
BioParadigms. SLC Tables. http://slc.bioparadigms.org. 2019.

49

